ENDORSED BY

Friday, April 30, 2010

8:00 am
Introduction & Pre-session audience survey
Hagop M. Kantarjian, MD – chairperson
John P. Leonard, MD – chairperson
Robert Z. Orlowski, MD, PhD – chairperson



Acute Leukemia Session
8:10 am
Debate: Is chemotherapy still useful for APL in the era of ATRA and arsenic trioxide?

ATRA + chemotherapy is still important
Harry P. Erba, MD, PhD

ATRA + non-chemotherapeutiic agents is better
Gary Schiller, MD

8:35 am
Debate: What is the most appropriate and effective therapy for elderly AML patients?

High Intensity therapy
Gary Schiller, MD

Low Intensity therapy
Harry Erba, MD, PhD

9:00 am
Emerging novel and promising therapeutic agents for AML
Stephen Nimer, MD

9:25 am
Coffee Break


Lymphoma Session I
9:45 am
Debate: Should the results of interim PET scans change the planned management of advanced Hodgkins Lymphoma or Diffuse Large B-cell Lymphoma?
Yes – Morton Coleman, MD
No – Craig Moskowitz, MD

10:10 am
Debate: Should surveillance CT scans be performed on DLBC Lymphoma patients who achieve a CR from frontline therapy?
Yes – Andrew D. Zelenetz, MD, PhD
No – Peter Martin, MD

10:35 am
Debate: What is the most appropriate second line therapy for advanced Follicular Lymphoma patients who relapse following frontline R-CHOP?
Autologous Stem Cell Transplant
Craig Moskowitz, MD

Radioimmunotherapy
Andrew D. Zelenetz, MD, PhD

Systemic chemotherapy
John P. Leonard, MD

11:05 am
What is the most appropriate management for stage I Follicular Lymphoma in a young patient – deciding when and with what to initiate therapy?
John P. Leonard, MD

11:35 am
Lunch

Myeloma Session I
12:40 pm
Debate: Since novel agents appear to abrogate the negative impact of poor risk cytogenetics, are cytogenetics by FISH still a necessary part of risk stratification for newly diagnosed Multiple Myeloma patients?
Yes – Sagar Lonial, MD
No – S. Vincent Rajkumar, MD

1:05 pm
Debate: What is the most appropriate frontline regimen for transplant ineligible Myeloma patients?
MPT – Steve P. Treon, MD, PhD
MPV – Sagar Lonial, MD
MPR – S. Vincent Rajkumar, MD

1:30 pm
The next great therapeutic challenge in Multiple Myeloma: Designing novel agents and combinations to overcome myeloma cell resistance to proteasome and immunomodulatory agents
Nikhil Munshi, MD

1:55 pm
Debate: For newly diagnosed SCT-eligible Myeloma patients the most appropriate induction therapy is:
A two drug regimen
Sagar Lonial, MD

A three drug regimen
Nikhil Munshi, MD

A four drug regimen
Shaji Kumar, MD

2:35 pm
Coffee Break

CML Session
2:55 pm
Debate: What is the best tyrosine kinase inhibitor for frontline therapy of CML?
Imatinib is still the standard of care
Eric Feldman, MD

New generation TKIs are the new standard of care
Hagop M. Kantarjian, MD

3:25 pm
Debate: What is the most appropriate salvage therapy for post-imatinib failure in CML?
Allogeneic SCT
Stephen Nimer, MD

Second generation TKIs
Jorge Cortes, MD

3:55 pm
Evolving & Promising therapeutic strategies for post-TKI failure in CML
Hagop M. Kantarjian, MD

4:20 pm
Summary & Post-session audience survey

4:30 pm
Adjourn

Saturday, May 1, 2010

8:00 am
Introduction & Pre-session audience survey
Hagop M. Kantarjian, MD – chairperson
John P. Leonard, MD – chairperson
Robert Z. Orlowski, MD, PhD – chairperson

CLL Session
8:05 am
Moderator: James Epstein, MD
Debate: FCR is the best frontline therapy for CLL patient ≥65 years of age

Yes, FCR is the new standard of care
Susan O’Brien, MD

No, chlorambucil based therapy is the standard of care
Asher A. Chanan-Khan, MD

8:30 am
Debate: How prominent should the roles of lenalidomide, bendamustine and ofatumumab be in the frontline therapy of CLL?
No significant role
Susan O’Brien, MD

Major significant role
Asher A. Chanan-Khan, MD

Myeloproliferative Neoplasm Session
8:55 am
Moderator: Richard T. Silver, MD
How I deal with the difficult questions in the Management of Essential Thrombocythemia
Ruben A. Mesa, MD

9:25 am
What is the role of allogeneic transplantation in Myeloproliferative Neoplasms?
Allo-SCT should be used earlier and more often in MPNs
Ronald Hoffman, MD

Allo-SCT should be used only when systemic therapy is inappropriate or has failed
Ruben A. Mesa, MD

Myeloma Session II
9:50 am
How I manage Multiple Myeloma patients who present with significant pre-existing illnesses or serious complications of the Myeloma:
A 68 year old former professional wrestler with a long history of back and joint problems is diagnosed with IgG-kappa Myeloma and multiple vertebral compression fractures – S. Vincent Rajkumar, MD

10:05 am
Coffee Break

10:25 am
How I manage Multiple Myeloma patients who present with significant pre-existing illnesses or serious complications of the Myeloma:
A 51 year old man presents with light chain Myeloma and a serum creatinine of 5.5 mg/dl
Rafael Fonseca, MD

A 46 year old woman with juvenile diabetes presents with IgG-lambda Myeloma and evidence of significant peripheral neuropathy
Shaji Kumar, MD

10:50 am
Debate: For newly diagnosed Multiple Myeloma patients who relapse from a ≥VGPR response more than 12 months following frontline therapy, what is the best salvage strategy?
Re-treat with the previously effective frontline therapy
Robert Z. Orlowski, MD

Alternate immunomodulatory based regimens with proteasome inhibitor- based regimens
Rafael Fonseca, MD

11:15 am
Debate: How should bisphosphonates be utilized in Multiple Myeloma patients responding to frontline therapy?
2 years of bisphosphonates therapy is appropriate for most patients
Speaker Invited

Briefer courses are more appropriate for most patients
Robert Z. Orlowski, MD, PhD

11:40 am
Debate: Do nucleoside analogues still have a role in the frontline therapy of symptomatic Waldenstroms Macroglobulinemia?
Yes – Shaji Kumar, MD
No – Steven P. Treon, MD, PhD

12:10 pm
Lunch

Lymphoma Session II
1:10 pm
Moderator: James Epstein, MD
Emerging and Promising Novel Agents for B-cell and T-cell Lymphomas
Owen A. O’Connor, MD, PhD

1:40 pm
Debate: Should treatment for limited stage non-bulky Hodgkins Lymphoma include radiation therapy?
Yes – Peter Martin, MD
No – Morton Coleman, MD

2:05 pm
Coffee Break

MDS Session
2:25 pm
Moderator: Richard T. Silver, MD
Debate: What is the best therapy for MDS patients with deletion 5q?
Lenalidomide is the best choice for all deletion 5q patients
Gail J. Roboz, MD

Lenalidomide is not the best choice for most deletion 5q patients
G. Garcia-Manero, MD

2:50 om
Debate: What is the best frontline therapy for intermediate-2 and high risk MDS?
Azacytidine is the standard of care
Gail J. Roboz, MD

The standard of care is not yet well defined
Eric Feldman, MD

3:15 pm
Novel & Evolving Therapeutic Strategies for MDS
Guillermo Garcia-Manero, MD

3:40 pm
Summary & Post-session audience survey

4:00 pm
Adjourn